Based on the current meta-analysis, IL-23 inhibitors demonstrate significant efficacy in improving joint and skin symptoms, achieving minimal disease activity, and resolving enthesitis and dactylitis in patients with psoriatic arthritis. This evidence concerns the gene IL37 and enthesitis.